The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparing treatment modalities for T2N0M0 muscle invasive bladder cancer: A propensity score analysis with the National Cancer Database.
 
Alberto Pieretti
No Relationships to Disclose
 
Mohamed Mohanna
No Relationships to Disclose
 
Saad Sabbagh
No Relationships to Disclose
 
Nicolas Muruve
No Relationships to Disclose
 
Hong Liang
No Relationships to Disclose
 
Christopher Fleming
No Relationships to Disclose
 
Christopher Weight
No Relationships to Disclose
 
Nima Almassi
No Relationships to Disclose
 
Georges-Pascal Haber
No Relationships to Disclose
 
Ashish M. Kamat
Honoraria - AstraZeneca (I); Tesaro (I)
Consulting or Advisory Role - Arquer Diagnostics; Asieris Pharmaceuticals; Astellas Pharma; Biological Dynamics; Bristol-Myers Squibb; CG Oncology; Cystotech; Eisai; EnGeneIC; FerGene; Imagin Medical; Imvax; Incyte; Janssen; Medac; Merck; Nonagen Bioscience; Pfizer; Photocure; Protara Therapeutics; Roche; Seagen; Sesen Bio; Theralase; TMC Innovation; Urogen pharma; US Biotest
Research Funding - Adolor; Bristol-Myers Squibb; FKD Therapies; Heat Biologics; Janssen/Taris; Merck; NIH; Patient-Centered Outcomes Research Institute (PCORI); Photocure; Seagen; SWOG; Taris BioMedical; The Leo & Anne Albert Institute for Bladder Cancer Care and Research (AIBCCR)
Patents, Royalties, Other Intellectual Property - Patent: CyPRIT (Cytokine Predictors of Response to Intravesical Therapy) joint with UT MD Anderson Cancer Center
Other Relationship - European Urology Oncology; International Bladder Cancer Group (IBCG); International Bladder Cancer Network; Journal of Urology; UroToday
 
Rafael Arteta-Bulos
No Relationships to Disclose
 
Colin P.N. Dinney
Honoraria - AstraZeneca; CG Oncology
Consulting or Advisory Role - AstraZeneca; CG Oncology; NCI
Research Funding - CG Oncology; NCI
Patents, Royalties, Other Intellectual Property - Creator of intellectual property owned by UT/MDACC related to the use of genetic alterations as a predictive biomarker for response to Nadofaragene firadenovec